REGULATORY
Bill Payers, Healthcare Providers Fighting over Financial Resources from Price Cuts for Long-listed Drugs
Yoshiaki Kamoya (executive officer, Shionogi & Co., Ltd.), who was recently appointed chairman of the Federation of Pharmaceutical Manufacturers’ Associations of Japan’s (FPMAJ) NHI Drug Price Study Committee, expressed strong concern about discussions on pricing of long-listed drugs in a…
To read the full story
REGULATORY
- Japan Approves Boey, Wider Labels for Hernexeos, Rinvoq, Tukysa, Pluvicto, and More
November 17, 2026
- Novartis Sjögren’s Drug, Meiji Antibiotic and More Up for Nov. 30 Panel Review
November 17, 2026
- Japan Grants Orphan Status to Rusfertide, Surovatamig, and Lots More
November 17, 2026
- Japan Extends Re-Examination for Saphnelo, Airwin, Fabhalta, Uplizna
November 17, 2026
- Takeda’s CLDN18.2 ADC Earns Sakigake Tag in Japan
November 17, 2026
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…





